Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nanoviricides Inc (NNVC)

Nanoviricides Inc (NNVC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,588
  • Shares Outstanding, K 10,677
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,450 K
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.17
Trade NNVC with:

Options Overview

Details
  • Implied Volatility 177.73%
  • Historical Volatility 206.82%
  • IV Percentile 75%
  • IV Rank 44.96%
  • IV High 238.91% on 11/03/20
  • IV Low 127.75% on 12/30/20
  • Put/Call Vol Ratio 0.32
  • Today's Volume 260
  • Volume Avg (30-Day) 1,342
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 6,566
  • Open Int (30-Day) 2,456

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.86 +37.31%
on 02/26/21
8.71 -39.15%
on 03/02/21
+0.59 (+12.53%)
since 02/05/21
3-Month
2.85 +85.96%
on 12/31/20
8.71 -39.15%
on 03/02/21
+1.43 (+36.95%)
since 12/04/20
52-Week
2.85 +85.96%
on 12/31/20
12.75 -58.43%
on 03/06/20
-2.78 (-34.41%)
since 03/05/20

Most Recent Stories

More News
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application

SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American:) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine technology...

NNVC : 5.30 (+13.98%)
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND

SHELTON, CT / ACCESSWIRE / February 17, 2021 / NanoViricides, Inc. (NYSE American: ) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 5.30 (+13.98%)
NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies

SHELTON, CT / ACCESSWIRE / February 8, 2021 / NanoViricides, Inc. (NYSE American: ) (the "Company") a global leader in the development of highly effective broad-spectrum antiviral therapies based on a...

NNVC : 5.30 (+13.98%)
Scientists Still Relentlessly Working to Develop Newest, More Advanced Antiviral Therapies for COVID-19 Treatments

, /PRNewswire/ -- The antivirals market consists of sales of antiviral drugs and related services. Antiviral drugs reduce the replication of viruses at different stages. Various type of viral infections...

NNVC : 5.30 (+13.98%)
TTOO : 1.6000 (-17.95%)
PFE : 34.39 (+0.56%)
SRNE : 8.88 (+0.79%)
MRNA : 132.19 (-0.08%)
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.'s President, Dr. Anil Diwan

SHELTON, CT / ACCESSWIRE / January 27, 2021 / NanoViricides, Inc. (NYSE American: ) (the "Company") a global leader in the development of highly effective broad-spectrum antiviral therapies based on a...

NNVC : 5.30 (+13.98%)
Global Market Outlook for the Coronavirus Vaccine Market to 2027, Featuring Moderna Inc, GeoVax, Inovio Pharmaceuticals and more

, /PRNewswire/ -- The report has been added to offering.

INO : 9.19 (+0.44%)
NNVC : 5.30 (+13.98%)
NVAX : 174.84 (+10.59%)
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA

SHELTON, CT / ACCESSWIRE / November 19, 2020 / NanoViricides, Inc. (NYSE Amer.:) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that Mr. Brian Zucker,...

NNVC : 5.30 (+13.98%)
Small Caps Daily Features NanoViricides' Rapid Advancement to Clinical Trials for its COVID-19 Therapy

New York, New York--(Newsfile Corp. - November 18, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on...

NNVC : 5.30 (+13.98%)
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress

SHELTON, CT / ACCESSWIRE / November 17, 2020 / NanoViricides, Inc. (NYSE American: ) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 5.30 (+13.98%)
Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments

, /PRNewswire/ -- Academia and industry around the world are working from basic research to advanced technology to alleviate the effects of the COVID–19 health crisis. The application of nanoscience...

NNVC : 5.30 (+13.98%)
INO : 9.19 (+0.44%)
ALT : 12.94 (-1.82%)
LLY : 206.92 (+3.18%)
PFE : 34.39 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development...

See More

Key Turning Points

3rd Resistance Point 6.73
2nd Resistance Point 6.03
1st Resistance Point 5.66
Last Price 5.30
1st Support Level 4.59
2nd Support Level 3.89
3rd Support Level 3.52

See More

52-Week High 12.75
Fibonacci 61.8% 8.97
Fibonacci 50% 7.80
Fibonacci 38.2% 6.63
Last Price 5.30
52-Week Low 2.85

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar